Gastrointestinal Cancer Vitals for April 2017

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

We screened 1662 studies on Gastrointestinal Cancer this month. These are the most important.


Gemcitabine and capecitabine recommended as new adjuvant therapy option in pancreatic cancer

Source: J Clin Oncol



  • ASCO guidelines for potentially curable pancreatic cancer updated on the basis of new clinical trial results.

 

 More details »  


Nivolumab shows promise in advanced esophageal SCC

Source: Lancet Oncol



  • There is no defined treatment strategy for patients with esophageal cancer who are refractory or intolerant to standard therapies.
  • In this phase 2 study, nivolumab showed promising antitumor activity with an acceptable safety profile.

 

 More details »  


HCC: segmental radioembolization tops chemoembolization

Source: J Vasc Interv Radiol



  • This retrospective study demonstrated a number of advantages of segmental radioembolization over chemoembolization for localized HCC, including better complete response rates, local tumor control, and PFS, with similar toxicity profiles.

 

 More details »  


Previous Vitals on Gastrointestinal Oncology: March '17February '17

Other recent Vitals: